Literature DB >> 20625943

Knockdown of Rad51 expression induces radiation- and chemo-sensitivity in osteosarcoma cells.

Li-Qing Du1, Yong Wang, Hong Wang, Jia Cao, Qiang Liu, Fei-Yue Fan.   

Abstract

Osteosarcoma is the common primary bone malignancy in children and young adults in Eastern countries. Resistance to ionizing radiation (IR) or drugs is an underlying mechanism contributing to the failure of therapy in these patients. Rad51 is the key protein of DNA homologous recombination repair. Although high expression of Rad51 is associated with enhanced resistance to DNA damage induced by chemicals and/or ionizing radiation, the relevance of Rad51 expression in osteosarcoma and its relationship with IR sensitivity and chemo-resistance is not well understood. In this study, we elucidated the possibility of using Rad51 in the treatment of human osteosarcoma in vitro. Changes in chemo- and radiation sensitivity in cultured osteosarcoma cells occurred after suppression of Rad51 expression, using a plasmid vector-mediated short hairpin RNA (shRNA) expression system. The suppression of Rad51 correlated with cell cycle arrest in the G2 phase and inhibited tumor cell proliferation. Our results suggest that Rad51 expression levels might play an important role in radiation- and chemo-sensitivity of human osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20625943     DOI: 10.1007/s12032-010-9605-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  19 in total

Review 1.  Chromosomal stability and the DNA double-stranded break connection.

Authors:  D C van Gent; J H Hoeijmakers; R Kanaar
Journal:  Nat Rev Genet       Date:  2001-03       Impact factor: 53.242

2.  Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity.

Authors:  Jeffery S Russell; Kristin Brady; William E Burgan; Michael A Cerra; Kelli A Oswald; Kevin Camphausen; Philip J Tofilon
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

3.  Mechanisms of drug sensitivity and resistance in cancer.

Authors:  Lorraine O'Driscoll
Journal:  Curr Cancer Drug Targets       Date:  2009-05       Impact factor: 3.428

4.  BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance.

Authors:  A Slupianek; C Schmutte; G Tombline; M Nieborowska-Skorska; G Hoser; M O Nowicki; A J Pierce; R Fishel; T Skorski
Journal:  Mol Cell       Date:  2001-10       Impact factor: 17.970

Review 5.  Primary bone osteosarcoma in the pediatric age: state of the art.

Authors:  Alessandra Longhi; Costantino Errani; Massimiliano De Paolis; Mario Mercuri; Gaetano Bacci
Journal:  Cancer Treat Rev       Date:  2006-07-24       Impact factor: 12.111

6.  Stable suppression of tumorigenicity by virus-mediated RNA interference.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

7.  Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma.

Authors:  Jun Ah Lee; Min Suk Kim; Dong Ho Kim; Jung Sub Lim; Ji Young Yoo; Jae Soo Koh; Soo-Yong Lee; Dae-Geun Jeon; Kyung Duk Park
Journal:  Pediatr Blood Cancer       Date:  2008-02       Impact factor: 3.167

8.  Role of Rad51 down-regulation and extracellular signal-regulated kinases 1 and 2 inactivation in emodin and mitomycin C-induced synergistic cytotoxicity in human non-small-cell lung cancer cells.

Authors:  Ying-Jhen Su; Min-Shao Tsai; Ya-Hsun Kuo; Yu-Fan Chiu; Chao-Min Cheng; Szu-Ting Lin; Yun-Wei Lin
Journal:  Mol Pharmacol       Date:  2009-12-30       Impact factor: 4.436

9.  Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines.

Authors:  A Sak; G Stueben; M Groneberg; W Böcker; M Stuschke
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

10.  DIDS, a chemical compound that inhibits RAD51-mediated homologous pairing and strand exchange.

Authors:  Takako Ishida; Yoshimasa Takizawa; Takashi Kainuma; Jin Inoue; Tsutomu Mikawa; Takehiko Shibata; Hidekazu Suzuki; Satoshi Tashiro; Hitoshi Kurumizaka
Journal:  Nucleic Acids Res       Date:  2009-03-30       Impact factor: 16.971

View more
  15 in total

1.  Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

2.  A role for homologous recombination proteins in cell cycle regulation.

Authors:  Kaja Kostyrko; Sandra Bosshard; Zuzanna Urban; Nicolas Mermod
Journal:  Cell Cycle       Date:  2015-06-30       Impact factor: 4.534

3.  RAD51 regulates CHK1 stability via autophagy to promote cell growth in esophageal squamous carcinoma cells.

Authors:  Xinyi Zhu; Qiuhui Pan; Nan Huang; Jianchun Wu; Ni Zhen; Fenyong Sun; Zhi Li; Qingyuan Yang
Journal:  Tumour Biol       Date:  2016-10-14

4.  Overexpression of Rad51 predicts poor prognosis and silencing of Rad51 increases chemo-sensitivity to doxorubicin in neuroblastoma.

Authors:  Yonghu Xu; Kai Chen; Yuanxia Cai; Cheng Cheng; Zihan Zhang; Guofeng Xu
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

5.  Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells.

Authors:  Tewodros Mamo; Ann C Mladek; Kris L Shogren; Carl Gustafson; Shiv K Gupta; Scott M Riester; Avudaiappan Maran; Mario Galindo; Andre J van Wijnen; Jann N Sarkaria; Michael J Yaszemski
Journal:  Biochem Biophys Res Commun       Date:  2017-03-12       Impact factor: 3.575

6.  Merlin-Deficient Schwann Cells Are More Susceptible to Radiation Injury than Normal Schwann Cells In Vitro.

Authors:  Erin Cohen; Stefanie Pena; Christine Mei; Olena Bracho; Brian Marples; Nagy Elsayyad; Stefania Goncalves; Michael Ivan; Paula V Monje; Xue-Zhong Liu; Cristina Fernandez-Valle; Fred Telischi; Christine T Dinh
Journal:  J Neurol Surg B Skull Base       Date:  2021-01-19

7.  Polymorphisms of homologous recombination genes and clinical outcomes of non-small cell lung cancer patients treated with definitive radiotherapy.

Authors:  Ming Yin; Zhongxing Liao; Yu-Jing Huang; Zhensheng Liu; Xianglin Yuan; Daniel Gomez; Li-E Wang; Qingyi Wei
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

8.  Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure.

Authors:  Ovidiu Balacescu; Loredana Balacescu; Oana Tudoran; Nicolae Todor; Meda Rus; Rares Buiga; Sergiu Susman; Bogdan Fetica; Laura Pop; Laura Maja; Simona Visan; Claudia Ordeanu; Ioana Berindan-Neagoe; Viorica Nagy
Journal:  BMC Cancer       Date:  2014-04-08       Impact factor: 4.430

9.  Chinese Herbal Mixture, Tien-Hsien Liquid, Induces G2/M Cycle Arrest and Radiosensitivity in MCF-7 Human Breast Cancer Cells through Mechanisms Involving DNMT1 and Rad51 Downregulation.

Authors:  Chih-Jung Yao; Jyh-Ming Chow; Chia-Ming Yang; Hui-Ching Kuo; Chia-Lun Chang; Hsin-Lun Lee; I-Chun Lai; Shuang-En Chuang; Gi-Ming Lai
Journal:  Evid Based Complement Alternat Med       Date:  2016-07-20       Impact factor: 2.629

10.  In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation.

Authors:  Maria Angelica Cortez; David Valdecanas; Sharareh Niknam; Heidi J Peltier; Lixia Diao; Uma Giri; Ritsuko Komaki; George A Calin; Daniel R Gomez; Joe Y Chang; John Victor Heymach; Andreas G Bader; James William Welsh
Journal:  Mol Ther Nucleic Acids       Date:  2015-12-15       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.